Bacterial Infection in COPD-Patients with Acute Respiratory Failure

Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(3):245-254

​ Avdeev S.N., Shanina A.G., Chuchalin A.G.
COPD exacerbation acute respiratory failure bacterial infections pathogens antimicrobial resistance
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(3):245-254

Abstract

To study the microbial and susceptibility patterns in COPD patients with acute respiratory failure (ARF) we performed a prospective cohort study in patients with ARF admitted to our acute care hospital. Quantitative cultures of expectorated sputum or bronchoalveolar lavage fluid (BALF) were performed. Patients with pneumonia and other causes of ARF were analyzed separately and were excluded from the study. One hundred seven COPD patients were included (92 males, age=66±8 years; APACHE II score=19±6; pH=7.27±0.07; PaCO2=61±15 mm Hg; PaO2=49±9 mm Hg), 70 patients received noninvasive ventilation and 18 patients – mechanical ventilation. Sputum or BALF culture diagnosed bacteriarelated exacerbation in 73 (68%) of participating COPD patients. Pathogens most frequently isolated were Pseudomonas spp. (29%), Haemophilus influenzae and Haemophilus parainfluenzae (20%), Streptococcus pneumoniae (14%). 90% of S. pneumoniae strains were sensitive to penicillin; Pseudomonas species revealed multiresistance in 19%. Multivariate logistic regression analysis showed that the only factor independently associated with isolation of Pseudomonas spp. was the frequency of hospitalizations – more than 4 times (OR 4.04, 95%CI 1.20–13.56, p=0.024).

  • 1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Publication Number 2701, April 2001: 1-100. The 2003 report is available on www.goldcopd.com.
  • 2. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21(Suppl. 41): S46-S53.
  • 3. Seemungal T.A.R., Donaldson G.C., Paul E.A., e.a. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 151:1418-22.
  • 4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-52.
  • 5. Zielinski J., MacNee W., Wedzicha J., e.a. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52:43-7.
  • 6. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (Suppl. 3): S43-S52.
  • 7. Ewig S., Rodriguez-Roisin R., Torres A. Indications for and choice of antibiotics in COPD. In: Similowski T, Whitelaw WA, Derenne J-P. (Eds.). Clinical management of chronic obstructive pulmonary disease. New York: Marcel Dekker Inc, 2002: 427-449.
  • 8. Anthonisen N.R., Manfreda J., Warren C.P.W., e.a. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
  • 9. Monso E., Ruiz J., Rosell A., e.a. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-20.
  • 10. Adams S., Melo J., Luther M., e.a. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest 2000; 117:1345-52.
  • 11. Leeper K.V., Jones A.M., Tillotson G. The changing bacterial etiology of chronic obstructive pulmonary disease. Chest 1997; 112:21.
  • 12. Fagon J.-Y., Chastre J., Trouillet J.-L., e.a. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Resp Dis 1990; 142:1004-8.
  • 13. Soler N., Torres A., Ewig S., e.a. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:1498-505.
  • 14. Eller J., Ede A., Schaberg T., Niederman M.S., e.a. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542-8.
  • 15. Nouira S., Marghli S., Belghith M., e.a. Once daily oral ofloxacin in in chronic obstructive pulmonary di se a se exacerbation requiring mechanical ventilation: a randomised placebo-controlled trail. Lancet 2001; 358:2020-5.
  • 16. Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975; 50:339-44.
  • 17. Cabello H., Torres A., Celis R., e.a. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997; 10:1137-44.
  • 18. Miravitlles M., Espinosa C., Fernandez-Laso E., e.a. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40-6.
  • 19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing (Vol. 17). Philadelphia, PA: NCCLS, 1997; 1: M57- M100.
  • 20. Groenewegen K.H., Wouters E.F. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 2003; 97:770-7.
  • 21. Evans S.A., Turner S.M., Bosch B.J., e.a. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9:1601-4.
  • 22. Vincent J.L. Microbial resistance lessons from the EPIC study. Intensive Care Med 2000; 26:S3-S8.
  • 23. Niederman M.S., Mantovani R., Schoch P., e.a. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by Pseudomonas species. Chest 1989; 95:947-52.
  • 24. Pang J.A., Cheng A., Chan H.S., e.a. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am Rev Resp Dis 1989; 139:14-7.
  • 25. Stockley R.A., O’Brien C., Pye A., Hill S.L. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117:1638-45.
  • 26. Wimberley N., Faling J., Barlett J.G. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979; 119:337-43.
  • 27. Soler N., Torres A., Celis R., e.a. Bronchial microbial patterns in non-severe exacerbations of COPD: a bronchoscopic study. Am J Respir Crit Care Med 1999; 161:A307.
  • 28. Seemungal T.A.R., Harper-Owen R., Bhowmik A., e.a. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000; 16:677-83.
  • 29. Mogulkoc N., Karakurt S., Isalska B., e.a. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160:349-53.
  • 30. Lieberman D., Lieberman D., Shmarkov O., e.a. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J 2002; 19:392-7.
  • 31. Hoban D., Felmingham D. The PROTEKT surveil lance study: antimicrobial susceptibility of Heamophilus influenzae and Morraxela catharralis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002; 50 (Suppl. 1):S49-S59.
  • 32. Felmingham D., Gruneberg R.N., and the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45:191-203.
  • 33. Состояние резистентности к антиинфекционным химиопрепаратам в России. Available on http://www.antibi otic.ru/index.php.
  • 34. European Antimicrobial Resistance Surveillance System. Database is available on www.earss.rivm.nl/PAGINA/interweb-site/home_earss.html.
  • 35. Козлов Р.С., Кречикова О.И., Сивая О.В., и др. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС–I). Клин микробиол антимикроб химиотер 2002; 4:267-77.
  • 36. Страчунский Л.С., Богданович Т.М. Состояние антибиотикорезистентности в России. В кн.: Антибактериальная терапия. Практическое руководство. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. Москва: РЦ «Фармединфо»; 2000: 7-11.
  • 37. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47:239-42.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared